Last reviewed 2026-04-20 · How we verify

Adrenon (ADRENALONE)

Phase 2 active Small molecule

Adrenon (generic name: ADRENALONE) is a adrenalone drug. It is currently in Phase 2 development.

Adrenon works by stimulating the body's 'fight or flight' response, mimicking the effects of epinephrine.

Adrenon (ADRENALONE) is a small molecule adrenalone, a synthetic analogue of epinephrine. Its exact target is unknown, but it is believed to work by stimulating the body's 'fight or flight' response. Adrenon is not FDA approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. As a result, key safety considerations and pharmacokinetic properties, such as half-life and bioavailability, are also not well established. Further research is needed to fully understand Adrenon's mechanism of action and clinical utility.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ADRENALONE
Drug class	adrenalone
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Imagine your body's 'fight or flight' response as a car's accelerator pedal. Adrenon is like a key that presses this pedal, causing your heart to beat faster, your blood vessels to constrict, and your body to prepare for action. This response is meant to help you react quickly to emergencies, but it can also have side effects if it's triggered unnecessarily.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Adrenon CI brief — competitive landscape report
Adrenon updates RSS · CI watch RSS

Frequently asked questions about Adrenon

What is Adrenon?

Adrenon (ADRENALONE) is a adrenalone drug.

How does Adrenon work?

Adrenon works by stimulating the body's 'fight or flight' response, mimicking the effects of epinephrine.

What is the generic name of Adrenon?

ADRENALONE is the generic (nonproprietary) name of Adrenon.

What drug class is Adrenon in?

Adrenon belongs to the adrenalone class. See all adrenalone drugs at /class/adrenalone.

What development phase is Adrenon in?

Adrenon is in Phase 2.

Drug class: All adrenalone drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing